Colin Baigent FFPH FRCP
Divisional Research Themes
- Clinical Epidemiology
- Cardiovascular Science
- Prof Rory Collins, Clinical Trial Service Unit, University of Oxford
- Dr Martin Landray, Clinical Trial Service Unit, University of Oxford
- Prof Sir Richard Peto, Clinical Trial Service Unit, University of Oxford
- Prof Carlo Patrono, University of Rome "La Sapienza"
- Dr David Wheeler, Royal Free Hospital
- Baigent Colin, Blackwell Lisa, Collins Rory, Emberson Jonathan, Godwin Jon, Peto Richard, Buring Julie, Hennekens Charles, Kearney Patricia, Meade Tom, Patrono Carlo, Roncaglioni Maria C, and Zanchetti Alberto (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678):1849-60.
- Kearney Patricia M, Baigent Colin, Godwin Jon, Halls Heather, Emberson Jonathan R, and Patrono Carlo (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332(7553):1302-8.
- Baigent C, Keech A, Kearney P M, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, and Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366(9493):1267-78.
- Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324(7329):71-86.
- Baigent C, Burbury K, and Wheeler D (2000) Premature cardiovascular disease in chronic renal failure. Lancet, 356(9224):147-52.
Colin Baigent’s main research interest is the use of large-scale evidence, typically involving randomized trials and meta-analyses of those trials, for the prevention and treatment of cardiovascular disease. He coordinates two separate areas of research:
(1) Large-scale collaborative meta-analyses of randomised trials: These very large projects generally involve detailed individual participant data from each trial, and the resulting analyses can provide reliable assessments of the benefits and risks of drug regimens for particular types of patients. They include the well-known Antithrombotic Trialists’ (ATT) and Cholesterol Treatment Trialists’ (CTT) Collaborations, which have helped establish the appropriate use of aspirin and statins in a wide range of people and conditions. More recently a new collaborative meta-analysis of trials has been established in order to assess the cardiovascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs and COX-2 inhibitors.
(2) Randomized trials of cardiovascular drugs in chronic kidney disease: Epidemiological associations between cardiovascular disease risk factors (eg, LDL cholesterol and blood pressure) and vascular disease outcomes are seriously distorted by “reverse causality” in advanced renal disease, producing associations that are the reverse of what might be expected. When treatments exist that can modify such risk factors, randomized trials of such treatments are an effective method for avoiding reverse causality and establishing the true relevance of those exposures to vascular disease. Colin has established an international collaboration of nephrologists which is conducting the Study of Heart and Renal Protection (SHARP), a randomized trial assessing the effects of cholesterol-lowering therapy in patients with chronic kidney disease. The trial involves 9,438 patients in 380 hospitals in 18 countries, and is scheduled for completion in 2010.